TB-500 claims on TikTok: what the research actually shows

A recent TikTok video by Ahmad Yasin MD describes TB-500 as a fragment of thymosin beta-4 (amino acids 17–23) and lists several potential benefits: supporting tissue repair, guiding cell migration, encouraging new blood vessel growth, aiding tendon and ligament recovery, improving mechanical function during rehab, limiting scar tissue, and even promoting hair growth. The clip is framed as educational and includes a disclaimer that it is not medical advice. But how well do these claims align with published research?

What the clip claims

The video presents TB-500 as a synthetic peptide that mimics the active region of thymosin beta-4, a naturally occurring protein involved in cytoskeletal regulation and cell motility. It suggests that TB-500 can help direct cells to injury sites, promote angiogenesis, and reduce fibrosis, leading to faster recovery from soft tissue injuries. It also mentions potential benefits for hair follicle health.

What the research neighborhood actually covers

Thymosin beta-4 (Tβ4) has been studied for decades in the context of wound healing, cardiac repair, and corneal regeneration. Preclinical studies have shown that Tβ4 can promote cell migration, angiogenesis, and reduce inflammation. However, most of this research uses the full-length protein (43 amino acids) or its N-terminal actin-binding domain, not the 7-amino-acid fragment (17–23) that is commonly referred to as TB-500 in the peptide community.

The specific fragment 17–23 has been studied in some animal models, particularly for its role in actin binding and cell migration. For example, a study in a rat model of corneal injury found that the fragment could promote epithelial healing. But the evidence base is far smaller than for the full protein, and many of the claims made in the video—such as improved mechanical function during rehab or reduced scar tissue—are extrapolated from studies using Tβ4, not the fragment.

Limits, missing context, and what a 15-second clip cannot show

The video’s brevity omits crucial context. First, it does not distinguish between the full-length thymosin beta-4 protein and the TB-500 fragment. While they share some properties, they are not identical. Second, the research cited is mostly preclinical (animal or cell-based); human clinical trials are limited. Third, the video does not mention that TB-500 is not approved by regulatory agencies for any medical use, and that its safety profile in humans is not well-characterized. Fourth, the claim about hair growth is based on a single study in mice, which is far from conclusive evidence for human use.

Finally, the video’s list of benefits is presented as a series of “may” statements, which is appropriate, but the overall tone implies a level of certainty that the research does not support. A 15-second clip cannot convey the nuances of study design, dosage, or the difference between in vitro and in vivo effects.

How this maps to catalog compounds

For researchers interested in thymosin beta-4, the catalog offers TB-500 (Thymosin Beta-4 Fragment 17–23) as a research compound. It is important to note that this is the fragment, not the full protein. If your research involves the full-length protein, you would need to source that separately. The catalog also includes BPC-157, another peptide often discussed in the context of tissue repair, but it is not directly relevant to this clip.

Research-use caveat

All peptides listed in the catalog are intended for research use only, not for human or animal consumption. They are not approved by the FDA or any other regulatory body. Researchers should handle them with appropriate safety precautions and ensure their studies comply with institutional and legal requirements.

Open the full video fact-check page (transcript, takeaways, embedded clip).